![Mark Fabian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mr. Mark Fabian is an Analyst at Arctic Asset Management AS.
He joined the firm in May 2021 with his work focus in company modelling, but also evaluation of products and pipelines in pharma and biotech companies as well as individual companies.
He has multiple years of experience in drug discovery, pharmaceutical and computational chemistry.
He completed internships at Roche, DNB and Amgen Scholars Program.
Mr. Fabian educated at Semmelweis University (PharmD) and Karolinska Institutet with MSc in Bioentrepreneurship.
Postes actifs de Mark Fabian
| Sociétés | Poste | Début |
|---|---|---|
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance AAM-Sweden employs an active approach that focuses on bringing long-term value creation to their clients. The firm’s Arctic Aurora LifeScience is a specialized global healthcare equity UCITS fund that invests primarily in European and US public life science companies. The investment strategy focuses on achieving excess return from investments in the biotechnology and pharmaceutical sector by investing in the most innovative companies developing new treatments that significantly change the life of patients to the benefit of society. | Analyst-Equity | 01/05/2021 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
1
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance AAM-Sweden employs an active approach that focuses on bringing long-term value creation to their clients. The firm’s Arctic Aurora LifeScience is a specialized global healthcare equity UCITS fund that invests primarily in European and US public life science companies. The investment strategy focuses on achieving excess return from investments in the biotechnology and pharmaceutical sector by investing in the most innovative companies developing new treatments that significantly change the life of patients to the benefit of society. | Finance |
